Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328629 | Critical Reviews in Oncology/Hematology | 2015 | 11 Pages |
Abstract
The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Berardino De Bari, Antonino Daidone, Filippo Alongi,